低收入和中等收入国家晚期早产子痫前期计划分娩或期待治疗(CRADLE-4):多中心、开放标签、随机对照试验
CRADLE-4是在印度和赞比亚9家医院开展的多中心、开放标签、随机对照试验,纳入565名34+0至36+6周子痫前期孕妇,1:1随机分为计划分娩组(284名孕妇,分析282名孕妇和301名新生儿)与期待治疗组(281名孕妇,分析280名孕妇和300名新生儿)。主要母体复合结局(死亡或严重并发症)计划分娩组154例(55%)vs期待治疗组168例(60%),校正RR 0.91(95%CI 0.79-1.05),无显著差异;主要围产儿复合结局(死产、新生儿死亡或新生儿病房住院>48小时)计划分娩组58例(19%)vs期待治疗组67例(22%),校正风险差-3.39%(90%CI -8.67至1.90),非劣效p<0.0001。计划分娩显著降低严重母体高血压(校正RR 0.83,95%CI 0.70-0.99)和死产(校正RR 0.25,95%CI 0.07-0.87)。作者认为在这些地区可安全提供计划分娩,并应考虑作为降低子痫前期相关死亡和疾病的干预措施。
要点
- 计划分娩组主要母体复合结局154/282(55%)vs期待治疗组168/280(60%),校正RR 0.91(95%CI 0.79-1.05),无显著差异。
- 计划分娩组主要围产儿复合结局58例(19%)vs期待治疗组67例(22%),校正风险差-3.39%(90%CI -8.67至1.90),非劣效p<0.0001。
- 计划分娩显著降低严重母体高血压(校正RR 0.83,95%CI 0.70-0.99)和死产(校正RR 0.25,95%CI 0.07-0.87)。
- 计划分娩组严重不良事件12例,期待治疗组21例。
- 作者认为在低收入和中等收入国家,临床医生可安全地向晚期早产子痫前期孕妇提供计划分娩。
适用人群与场景
- 印度和赞比亚9家医院及转诊机构中妊娠34+0至36+6周的子痫前期孕妇。
处置流程与药物剂量
- 计划分娩组在34+0至36+6周妊娠期间进行计划分娩;期待治疗组采用期待管理。
研究设计与关键结果
- 研究类型:平行组、多中心、开放标签、随机对照试验;纳入565名孕妇,计划分娩组284名(分析282名孕妇和301名新生儿),期待治疗组281名(分析280名孕妇和300名新生儿)。
- 主要母体结局(死亡或严重并发症复合):计划分娩组154例(55%)vs期待治疗组168例(60%),校正RR 0.91(95%CI 0.79-1.05),无显著差异。
- 主要围产儿结局(死产、新生儿死亡或新生儿病房住院>48小时的复合):按意向治疗分析,计划分娩组58例(19%)vs期待治疗组67例(22%),校正风险差-3.39%(90%CI -8.67至1.90),非劣效p<0.0001;符合方案分析结果相似。
- 关键次要终点:计划分娩显著降低严重母体高血压(校正RR 0.83,95%CI 0.70-0.99)和死产(校正RR 0.25,95%CI 0.07-0.87)。
- 不良事件:计划分娩组严重不良事件12例,期待治疗组21例。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验;主要母体结局采用优效性假设,主要围产儿结局采用非劣效性假设(非劣效界值为10%差异)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在低收入和中等收入国家,临床医生可安全地向晚期早产子痫前期孕妇提供计划分娩。
- 作者认为,计划分娩可降低死产,且不增加新生儿病房住院或新生儿疾病,并降低严重母体高血压风险;因此应考虑将34周起的计划分娩作为降低这些地区子痫前期相关死亡和疾病的干预措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pre-eclampsia is a leading cause of maternal and perinatal mortality. Evidence regarding interventions in a low-income or middle-income setting is scarce. We aimed to evaluate whether planned delivery between 34+ 0 and 36+ 6 weeks' gestation can reduce maternal mortality and morbidity without increasing perinatal complications in India and Zambia.
METHODS: In this parallel-group, multicentre, open-label, randomised controlled trial, we compared planned delivery versus expectant management in women with pre-eclampsia from 34+ 0 to 36+ 6 weeks' gestation. Participants were recruited from nine hospitals and referral facilities in India and Zambia and randomly assigned to planned delivery or expectant management in a 1:1 ratio by a secure web-based randomisation facility hosted by MedSciNet. Randomisation was stratified by centre and minimised by parity, single-fetus pregnancy or multi-fetal pregnancy, and gestational age. The primary maternal outcome was a composite of maternal mortality or morbidity with a superiority hypothesis. The primary perinatal outcome was a composite of one or more of: stillbirth, neonatal death, or neonatal unit admission of more than 48 h with a non-inferiority hypothesis (margin of 10% difference). Analyses were by intention to treat, with an additional per-protocol analysis for the perinatal outcome. The trial was prospectively registered with ISRCTN, 10672137. The trial is closed to recruitment and all follow-up has been completed.
FINDINGS: Between Dec 19, 2019, and March 31, 2022, 565 women were enrolled. 284 women (282 women and 301 babies analysed) were allocated to planned delivery and 281 women (280 women and 300 babies analysed) were allocated to expectant management. The incidence of the primary maternal outcome was not significantly different in the planned delivery group (154 [55%]) compared with the expectant management group (168 [60%]; adjusted risk ratio [RR] 0·91, 95% CI 0·79 to 1·05). The incidence of the primary perinatal outcome by intention to treat was non-inferior in the planned delivery group (58 [19%]) compared with the expectant management group (67 [22%]; adjusted risk difference -3·39%, 90% CI -8·67 to 1·90; non-inferiority p<0·0001). The results from the per-protocol analysis were similar. There was a significant reduction in severe maternal hypertension (adjusted RR 0·83, 95% CI 0·70 to 0·99) and stillbirth (0·25, 0·07 to 0·87) associated with planned delivery. There were 12 serious adverse events in the planned delivery group and 21 in the expectant management group.
INTERPRETATION: Clinicians can safely offer planned delivery to women with late preterm pre-eclampsia, in a low-income or middle-income country. Planned delivery reduces stillbirth, with no increase in neonatal unit admissions or neonatal morbidity and reduces the risk of severe maternal hypertension. Planned delivery from 34 weeks' gestation should therefore be considered as an intervention to reduce pre-eclampsia associated mortality and morbidity in these settings.
FUNDING: UK Medical Research Council and Indian Department of Biotechnology.
参考来源
- Beardmore-Gray A, Vousden N, Seed PT, et al. Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial. Lancet. 2023. PMID: 37393919. doi:10.1016/S0140-6736(23)00688-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。